Association of low body weight with clinical outcomes in elderly atrial fibrillation patients receiving apixaban—J-ELD AF registry subanalysis

T Kadosaka, T Nagai, S Suzuki, I Sakuma… - … Drugs and Therapy, 2022 - Springer
Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation

Y Murakawa, T Ikeda, S Ogawa, T Kitazono… - Heart and vessels, 2020 - Springer
This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …

[引用][C] Efficacy and Safety of Direct Oral Anticoagulants (DOACs) in Morbidly Obese Patients

C Kalani, EA Henry, T Alexander, G Udeani, S Surani - Chest, 2018 - journal.chestnet.org
PURPOSE: There is a paucity of clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy and …

[引用][C] Use of oral anticoagulants in obese patients

KK Graves, K Edholm, SA Johnson - JSM Atheroscler, 2017

Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review …

M Grymonprez, TL De Backer, S Steurbaut… - … Drugs and Therapy, 2021 - Springer
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry

N Ardeshna, T Feldeisen, X Kong… - Vascular …, 2024 - journals.sagepub.com
Introduction: Direct oral anticoagulants (DOACs) have overtaken warfarin in the treatment of
nonvalvular atrial fibrillation (AF) and venous thromboembolism (VTE). Limited data explore …

Obesity paradox in atrial fibrillation and its relation with the new oral anticoagulants

AIN Lima Filho, MC do Rego Barros… - Current Cardiology …, 2022 - benthamdirect.com
Obesity, a chronic disease established as a global epidemic by the World Health
Organization, is considered a risk factor for atrial fibrillation (AF), the most common …

Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data

M Alalawneh, O Rachid, I Abdallah, A Mahfouz… - European Journal of …, 2023 - Springer
Purpose To investigate real-world prescribing trends and clinical outcomes based on body
mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This …

Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients

C Kalani, E Awudi, T Alexander, G Udeani… - Hospital …, 2019 - Taylor & Francis
Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Observed apixaban anti-xa levels in obese patients

W Harkness, O Pipitone, J Joss… - Annals of …, 2022 - journals.sagepub.com
Background: Recent guidelines suggest that, for venous thromboembolism (VTE), standard
doses of apixaban are appropriate in patients with body mass index (BMI)> 40 kg/m2 or> …